Alendronat Aristo Veckotablett
Alendronic acid 70 mg — Weekly bisphosphonate tablet for osteoporosis
Quick Facts about Alendronat Aristo Veckotablett
Key Takeaways
- Once-weekly dosing: Take one 70 mg tablet on the same day each week, first thing in the morning on an empty stomach with plain water
- Stay upright for 30 minutes: After taking the tablet, remain sitting or standing upright and do not eat, drink, or take other medicines for at least 30 minutes
- Proven fracture reduction: Clinical trials show alendronic acid reduces the risk of vertebral fractures by approximately 47% and hip fractures by approximately 51% over 3 years
- Long-term treatment: Typically prescribed for 3–5 years with reassessment; some patients may benefit from longer treatment
- Supplement with calcium and vitamin D: Adequate calcium and vitamin D intake is essential during treatment, but supplements must be taken separately from alendronic acid
What Is Alendronat Aristo Veckotablett and What Is It Used For?
Alendronat Aristo Veckotablett is a bisphosphonate medicine containing alendronic acid 70 mg, taken once a week to treat osteoporosis in postmenopausal women. It works by inhibiting the cells that break down bone (osteoclasts), thereby slowing bone loss, increasing bone density, and reducing the risk of fractures.
Alendronic acid belongs to the bisphosphonate class of drugs, which are the most widely prescribed medications for the treatment and prevention of osteoporosis worldwide. The medication is manufactured by Aristo Pharma and is bioequivalent to other alendronate 70 mg formulations available internationally. The once-weekly dosing schedule was developed to improve patient convenience and adherence compared to the original daily formulation, while providing equivalent efficacy in building bone density.
Osteoporosis is a systemic skeletal disease characterized by low bone mass and deterioration of bone tissue, leading to increased bone fragility and susceptibility to fracture. It affects an estimated 200 million people worldwide, according to the International Osteoporosis Foundation (IOF). Postmenopausal women are particularly vulnerable due to the decline in estrogen levels, which accelerates bone loss. In the first five to seven years after menopause, women can lose up to 20% of their bone density.
Alendronic acid works at the molecular level by binding to hydroxyapatite crystals on bone surfaces, particularly at sites of active bone resorption. When osteoclasts attempt to dissolve bone mineral and resorb bone tissue, they take up the alendronic acid, which disrupts their cellular processes and induces osteoclast apoptosis (programmed cell death). This mechanism effectively slows down the rate of bone turnover, allowing bone formation by osteoblasts to catch up with bone resorption, resulting in a net increase in bone mineral density over time.
The Fracture Intervention Trial (FIT), one of the landmark studies for alendronate, demonstrated that 70 mg weekly alendronic acid (equivalent to 10 mg daily) significantly reduces the risk of vertebral fractures by approximately 47%, hip fractures by approximately 51%, and wrist fractures by approximately 48% over a three-year treatment period. These results have been confirmed in subsequent meta-analyses and real-world evidence studies.
Osteoporosis is often called the “silent disease” because bone loss occurs without symptoms until a fracture happens. A bone density scan (DEXA scan) is the standard diagnostic tool. If you have been prescribed Alendronat Aristo Veckotablett, it is because your doctor has determined that you are at increased risk of fractures and would benefit from treatment.
What Should You Know Before Taking Alendronat Aristo Veckotablett?
Before taking Alendronat Aristo Veckotablett, your doctor needs to know about any esophageal problems, kidney disease, low calcium levels, or inability to remain upright for 30 minutes. This medicine is not suitable for everyone and has specific contraindications that must be carefully evaluated.
Contraindications
You must not take Alendronat Aristo Veckotablett if any of the following apply to you:
- Esophageal abnormalities that delay esophageal emptying, such as stricture or achalasia
- Inability to stand or sit upright for at least 30 minutes after taking the tablet
- Hypocalcemia (low blood calcium levels) — this must be corrected before starting treatment
- Severe kidney impairment (creatinine clearance below 35 ml/min)
- Known hypersensitivity to alendronic acid or any of the excipients in the tablet
Warnings and Precautions
Several important precautions should be considered before and during treatment with alendronic acid. Upper gastrointestinal adverse reactions such as esophagitis, esophageal ulcers, and esophageal erosions have been reported in patients receiving bisphosphonates. These reactions can be serious and may require hospitalization. The risk is significantly reduced when patients carefully follow the dosing instructions, particularly remaining upright and not lying down after taking the tablet.
Osteonecrosis of the jaw (ONJ) is a rare but recognized side effect of bisphosphonate therapy, occurring more frequently with intravenous bisphosphonates used in cancer treatment but also reported rarely with oral bisphosphonates used for osteoporosis. Patients should maintain good dental hygiene and inform their dentist that they are taking alendronic acid before any dental surgery. Risk factors for ONJ include dental extractions, poor oral hygiene, cancer, chemotherapy, corticosteroid use, and pre-existing dental disease.
Atypical femoral fractures have been reported rarely in patients taking bisphosphonates for extended periods. These are stress fractures in the thigh bone (femur) that can occur with minimal or no trauma. Patients should be advised to report any new or unusual thigh, hip, or groin pain during treatment, as this may be an early symptom of an atypical fracture. The risk increases with longer duration of bisphosphonate use, which is one of the reasons treatment duration is typically reassessed after 3–5 years.
Pregnancy and Breastfeeding
Alendronat Aristo Veckotablett is intended for use in postmenopausal women and should not be taken during pregnancy or breastfeeding. Alendronic acid has been shown to cause developmental toxicity in animal studies, including incomplete fetal ossification. There are no adequate human data on use during pregnancy. If a woman of childbearing potential is prescribed alendronic acid for other indications such as glucocorticoid-induced osteoporosis, effective contraception should be used. Alendronic acid is incorporated into the bone matrix and may be gradually released over years; the clinical significance of this for a future pregnancy is unknown.
Failure to follow the dosing instructions carefully can result in esophageal irritation, ulceration, or perforation, which can be serious and may require hospitalization. Always take the tablet with a full glass of plain water (not mineral water, coffee, tea, or juice), and remain fully upright (do not lie down) for at least 30 minutes after taking it.
How Does Alendronat Aristo Veckotablett Interact with Other Drugs?
Alendronic acid absorption is significantly affected by food, drinks, and many medications. Calcium, antacids, and mineral supplements must not be taken within 30 minutes of alendronic acid. NSAIDs may increase the risk of gastrointestinal side effects when used together.
Alendronic acid has very low oral bioavailability (approximately 0.6–0.7% on an empty stomach), and this can be further reduced by the presence of food, beverages, or other medications in the stomach. Even a simple cup of coffee or orange juice can reduce absorption by up to 60%. This is why it is crucial to take the tablet on a completely empty stomach with only plain water and to wait at least 30 minutes before eating, drinking, or taking any other medicines.
Patients taking alendronic acid should also be aware that certain medications can enhance or worsen side effects. Non-steroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen and aspirin are associated with gastrointestinal irritation, and their concurrent use with alendronic acid may increase the risk of upper GI adverse reactions. While occasional use of NSAIDs is generally acceptable, regular daily use should be discussed with a healthcare provider.
| Interacting Drug | Type | Effect | Recommendation |
|---|---|---|---|
| Calcium supplements | Absorption reduction | Significantly reduces alendronate absorption | Take at least 30 minutes after alendronate |
| Antacids (Al/Mg hydroxide) | Absorption reduction | Binds alendronate in the stomach, preventing absorption | Take at least 30 minutes after alendronate |
| Iron supplements | Absorption reduction | May reduce alendronate absorption | Take at least 30 minutes after alendronate |
| NSAIDs (ibuprofen, naproxen) | Additive GI effects | Increased risk of gastrointestinal irritation and ulcers | Use with caution; avoid regular daily use |
| Aspirin | Additive GI effects | Increased risk of upper GI adverse events | Use with caution at doses >325 mg/day |
| Proton pump inhibitors (PPIs) | Potential concern | PPIs may reduce calcium absorption; possible reduced alendronate efficacy | Monitor bone density; ensure adequate calcium intake |
| Corticosteroids (oral) | Bone health interaction | Corticosteroids cause bone loss; alendronate can help prevent this | May be used together under medical supervision |
Major Interactions
The most clinically significant interactions involve substances that reduce the absorption of alendronic acid. Calcium supplements, antacids containing aluminum or magnesium, and iron preparations form insoluble complexes with alendronate in the gastrointestinal tract, rendering the drug virtually ineffective if taken simultaneously. This is not a reason to avoid these supplements, as many patients on alendronic acid require calcium and vitamin D supplementation. Rather, patients should simply ensure that a minimum of 30 minutes (preferably longer) elapses after taking alendronic acid before consuming any food, supplements, or other medications.
Minor Interactions
Proton pump inhibitors (PPIs) such as omeprazole and esomeprazole are commonly co-prescribed in patients taking alendronic acid. While PPIs do not directly interact with alendronate absorption, some studies suggest that long-term PPI use may impair calcium absorption and potentially reduce the bone-protective effects of bisphosphonate therapy. The clinical significance of this interaction is debated, but patients on both medications should ensure adequate calcium and vitamin D intake and have regular bone density monitoring.
What Is the Correct Dosage of Alendronat Aristo Veckotablett?
The recommended dose is one 70 mg tablet taken once weekly on the same day each week. The tablet must be taken first thing in the morning on an empty stomach with a full glass of plain water. Patients must remain upright and avoid food, drink, and other medicines for at least 30 minutes.
Adults
Postmenopausal Osteoporosis — Treatment
Dose: 70 mg once weekly (one tablet per week)
When: Choose a day of the week that best fits your schedule. Take the tablet first thing in the morning, at least 30 minutes before your first food, drink, or other medication.
How: Swallow the tablet whole with a full glass (at least 200 ml) of plain water only. Do not chew, crush, dissolve, or suck the tablet. Do not take with mineral water, coffee, tea, juice, or milk.
After taking: Remain fully upright (sitting or standing) for at least 30 minutes and until after your first meal of the day. Do not lie down during this period.
Postmenopausal Osteoporosis — Prevention
Dose: 70 mg once weekly, with the same administration instructions as for treatment. Some guidelines recommend a lower dose (35 mg weekly or 5 mg daily) for prevention, but the 70 mg weekly formulation is commonly used when both treatment and prevention are indicated.
| Patient Group | Dose | Frequency | Notes |
|---|---|---|---|
| Postmenopausal women | 70 mg | Once weekly | First-line treatment for osteoporosis |
| Mild renal impairment | 70 mg | Once weekly | No dose adjustment needed (CrCl ≥35 ml/min) |
| Severe renal impairment | Not recommended | — | Contraindicated if CrCl <35 ml/min |
| Elderly (≥65 years) | 70 mg | Once weekly | No dose adjustment needed |
Children
Alendronat Aristo Veckotablett is not indicated for use in children or adolescents under the age of 18. The safety and efficacy of alendronic acid in pediatric patients have not been established for the treatment of osteoporosis. In rare cases, alendronic acid has been studied in children with osteogenesis imperfecta, but this is outside the scope of this product's approved indications and should only be managed by specialist pediatric bone health services.
Elderly
No dose adjustment is required for elderly patients. In clinical trials, there was no age-related difference in the efficacy or safety profile of alendronic acid. However, elderly patients may be more susceptible to gastrointestinal adverse effects and should pay particular attention to the dosing instructions. Patients who have difficulty swallowing or who cannot remain upright for 30 minutes should discuss alternative osteoporosis treatments with their doctor.
Missed Dose
If you forget to take your weekly dose, take one tablet on the morning after you remember. Then return to your regular weekly schedule on your chosen day. Do not take two tablets on the same day. If you accidentally miss more than one week, simply resume your regular schedule — do not attempt to “catch up” by taking multiple tablets.
Overdose
In the event of an overdose, symptoms may include hypocalcemia (low blood calcium), hypophosphatemia (low blood phosphate), and upper gastrointestinal adverse events such as nausea, vomiting, heartburn, esophagitis, and gastritis. Milk or antacids should be given to bind the alendronate. Due to the risk of esophageal irritation, vomiting should not be induced, and the patient should remain fully upright. In cases of significant overdose, seek medical attention immediately.
International guidelines, including those from NICE and the American Association of Clinical Endocrinologists (AACE), recommend reassessing the need for continued bisphosphonate therapy after 3–5 years. Patients at low to moderate fracture risk may be candidates for a “drug holiday” (temporary cessation), while those at high risk may benefit from continued treatment. Your doctor will assess your individual situation based on bone density results and fracture risk factors.
What Are the Side Effects of Alendronat Aristo Veckotablett?
The most common side effects of alendronic acid are gastrointestinal, including abdominal pain, dyspepsia, constipation, diarrhea, and acid reflux. Musculoskeletal pain (bone, muscle, or joint pain) is also common. Most side effects are mild and can be minimized by carefully following the dosing instructions.
Like all medicines, Alendronat Aristo Veckotablett can cause side effects, although not everyone experiences them. The following side effects have been reported in clinical trials and post-marketing surveillance. Gastrointestinal side effects are the most frequently reported and are often related to improper administration of the tablet. Adherence to the dosing instructions — taking the tablet with a full glass of water, remaining upright, and waiting 30 minutes before eating — significantly reduces the incidence and severity of these effects.
It is important to distinguish between common, manageable side effects and rare but serious adverse reactions that require immediate medical attention. If you experience difficulty swallowing, chest pain, new or worsening heartburn, or severe bone, joint, or muscle pain, you should stop taking the medication and contact your healthcare provider promptly.
Common
- Headache
- Abdominal pain, stomach discomfort
- Dyspepsia (indigestion)
- Constipation
- Diarrhea
- Flatulence (gas)
- Acid reflux, heartburn
- Esophageal ulcer
- Musculoskeletal pain (bone, muscle, joint pain)
Uncommon
- Nausea and vomiting
- Esophagitis (inflammation of the esophagus)
- Esophageal erosions
- Gastritis (stomach inflammation)
- Melena (dark, tarry stools)
- Bloating
- Skin rash, itching
- Erythema (redness of the skin)
- Transient decrease in blood calcium and phosphate
- Dizziness
- Taste disturbance (dysgeusia)
Rare
- Esophageal stricture (narrowing of the esophagus)
- Oropharyngeal ulceration (mouth and throat ulcers)
- Upper gastrointestinal perforation, ulcers, or bleeding
- Osteonecrosis of the jaw (ONJ)
- Atypical femoral fractures
- Uveitis, scleritis, or episcleritis (eye inflammation)
- Hypersensitivity reactions including urticaria and angioedema
- Stevens-Johnson syndrome (very rare)
- Symptomatic hypocalcemia
If you experience any side effects, including those not listed above, talk to your doctor or pharmacist. You can also report side effects directly to your national pharmacovigilance authority to help provide more information on the safety of this medicine.
Difficulty or pain when swallowing, chest pain, new or worsening heartburn, signs of jaw problems (pain, swelling, numbness, loose teeth), unusual pain in the thigh or groin, or signs of a severe allergic reaction (swelling of the face, lips, tongue, or throat; difficulty breathing; skin rash with blistering).
How Should You Store Alendronat Aristo Veckotablett?
Store Alendronat Aristo Veckotablett below 25°C in the original packaging to protect from moisture. Keep out of the sight and reach of children. Do not use after the expiry date printed on the packaging.
Proper storage of medicines is essential to maintain their effectiveness and safety throughout the shelf life. Alendronat Aristo Veckotablett should be stored at room temperature, below 25°C (77°F). The tablets should be kept in their original blister packaging until the time of use to protect them from moisture and light. Do not transfer tablets to other containers.
Keep this medicine out of the sight and reach of children. Children may be particularly vulnerable to the effects of bisphosphonates, and accidental ingestion could cause serious harm. The tablet should be stored in a secure location, preferably in a locked medicine cabinet.
Do not use Alendronat Aristo Veckotablett after the expiry date stated on the blister and outer carton. The expiry date refers to the last day of that month. Do not throw away medicines via wastewater or household waste. Ask your pharmacist how to dispose of medicines you no longer use — these measures help to protect the environment.
What Does Alendronat Aristo Veckotablett Contain?
Each tablet contains 70 mg of alendronic acid (as alendronate sodium trihydrate) as the active ingredient. The inactive ingredients include microcrystalline cellulose, lactose monohydrate, croscarmellose sodium, and magnesium stearate.
The active substance is alendronic acid. Each tablet contains 70 mg of alendronic acid, equivalent to 91.37 mg of alendronate sodium trihydrate. The sodium salt form is used because it has better stability and water solubility compared to free alendronic acid.
The other ingredients (excipients) are:
- Microcrystalline cellulose — a bulking agent and binder that gives the tablet its structure
- Lactose monohydrate — a filler; patients with rare hereditary galactose intolerance, total lactase deficiency, or glucose-galactose malabsorption should not take this medicine
- Croscarmellose sodium — a disintegrant that helps the tablet break down in the stomach
- Magnesium stearate — a lubricant used during the manufacturing process
The tablets are white to off-white, round, biconvex tablets. They may be marked with an identification code on one side. The tablets are available in blister packs of 4 tablets (one month’s supply) or 12 tablets (three months’ supply), depending on the market.
This medicine contains lactose monohydrate. If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicinal product. The amount of lactose per tablet is small and is generally well tolerated by people with mild lactose intolerance.
Frequently Asked Questions
Medical References and Sources
This article is based on current medical research and international guidelines. All claims are supported by scientific evidence from peer-reviewed sources.
- Black DM, et al. (1996). "Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures." The Lancet. 348(9041):1535-1541. Fracture Intervention Trial (FIT) — landmark study demonstrating alendronate efficacy in fracture reduction. Evidence level: 1A
- Wells GA, et al. (2008). "Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women." Cochrane Database of Systematic Reviews. Systematic review of alendronate efficacy and safety for osteoporosis prevention and treatment.
- International Osteoporosis Foundation (IOF) (2024). "Osteoporosis Prevention and Treatment Guidelines." International consensus guidelines on osteoporosis management including bisphosphonate therapy.
- NICE Clinical Guideline CG146 (2024, updated). "Osteoporosis: assessing the risk of fragility fracture." UK National Institute for Health and Care Excellence guidelines on osteoporosis assessment and management.
- Camacho PM, et al. (2020). "American Association of Clinical Endocrinologists/American College of Endocrinology Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis." Endocrine Practice. 26(Suppl 1):1-46. AACE/ACE comprehensive guidelines on osteoporosis diagnosis and treatment including drug therapy recommendations.
- European Medicines Agency (EMA). "Summary of Product Characteristics: Alendronic acid 70 mg once weekly tablets." Official regulatory document with complete prescribing information for alendronic acid in the European Union.
- World Health Organization (WHO) (2023). "Model List of Essential Medicines." Alendronic acid is listed as an essential medicine by the WHO for the treatment of osteoporosis.
Evidence grading: This article uses the GRADE framework (Grading of Recommendations Assessment, Development and Evaluation) for evidence-based medicine. Evidence level 1A represents the highest quality of evidence, based on systematic reviews of randomized controlled trials.
iMedic Editorial Standards
📋 Peer Review Process
All medical content is reviewed by at least two licensed specialist physicians before publication.
🔎 Fact-Checking
All medical claims are verified against peer-reviewed sources and international guidelines.
🔄 Update Frequency
Content is reviewed and updated at least every 12 months or when new research emerges.
✏ Corrections Policy
Any errors are corrected immediately with transparent changelog.
Medical Editorial Board: iMedic has an independent medical editorial board consisting of specialist physicians in rheumatology, pharmacology, endocrinology, and internal medicine.